Literature DB >> 32417852

Sex-specific neurobiological actions of prophylactic (R,S)-ketamine, (2R,6R)-hydroxynorketamine, and (2S,6S)-hydroxynorketamine.

Briana K Chen1, Victor M Luna2,3, Christina T LaGamma2,4, Xiaoming Xu5,6, Shi-Xian Deng5,6, Raymond F Suckow3,7, Thomas B Cooper3,7, Abhishek Shah8, Rebecca A Brachman3, Indira Mendez-David9, Denis J David9, Alain M Gardier9, Donald W Landry5,6, Christine A Denny10,11.   

Abstract

Enhancing stress resilience in at-risk populations could significantly reduce the incidence of stress-related psychiatric disorders. We have previously reported that the administration of (R,S)-ketamine prevents stress-induced depressive-like behavior in male mice, perhaps by altering α-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid receptor (AMPAR)-mediated transmission in hippocampal CA3. However, it is still unknown whether metabolites of (R,S)-ketamine can be prophylactic in both sexes. We administered (R,S)-ketamine or its metabolites (2R,6R)-hydroxynorketamine ((2R,6R)-HNK) and (2S,6S)-hydroxynorketamine ((2S,6S)-HNK) at various doses 1 week before one of a number of stressors in male and female 129S6/SvEv mice. Patch clamp electrophysiology was used to determine the effect of prophylactic drug administration on glutamatergic activity in CA3. To examine the interaction between ovarian hormones and stress resilience, female mice also underwent ovariectomy (OVX) surgery and a hormone replacement protocol prior to drug administration. (2S,6S)-HNK and (2R,6R)-HNK protected against distinct stress-induced behaviors in both sexes, with (2S,6S)-HNK attenuating learned fear in male mice, and (2R,6R)-HNK preventing stress-induced depressive-like behavior in both sexes. (R,S)-ketamine and (2R,6R)-HNK, but not (2S,6S)-HNK, attenuated large-amplitude AMPAR-mediated bursts in hippocampal CA3. All three compounds reduced N-methyl-D-aspartate receptor (NMDAR)-mediated currents 1 week after administration. Furthermore, ovarian-derived hormones were necessary for and sufficient to restore (R,S)-ketamine- and (2R,6R)-HNK-mediated prophylaxis in female mice. Our data provide further evidence that resilience-enhancing prophylactics may alter AMPAR-mediated glutamatergic transmission in CA3. Moreover, we show that prophylactics against stress-induced depressive-like behavior can be developed in a sex-specific manner and demonstrate that ovarian hormones are necessary for the prophylactic efficacy of (R,S)-ketamine and (2R,6R)-HNK in female mice.

Entities:  

Year:  2020        PMID: 32417852      PMCID: PMC7360766          DOI: 10.1038/s41386-020-0714-z

Source DB:  PubMed          Journal:  Neuropsychopharmacology        ISSN: 0893-133X            Impact factor:   7.853


  60 in total

Review 1.  Depression: perspectives from affective neuroscience.

Authors:  Richard J Davidson; Diego Pizzagalli; Jack B Nitschke; Katherine Putnam
Journal:  Annu Rev Psychol       Date:  2002       Impact factor: 24.137

Review 2.  Gender differences in depression. Critical review.

Authors:  M Piccinelli; G Wilkinson
Journal:  Br J Psychiatry       Date:  2000-12       Impact factor: 9.319

3.  Efficacy and Safety of Intranasal Esketamine Adjunctive to Oral Antidepressant Therapy in Treatment-Resistant Depression: A Randomized Clinical Trial.

Authors:  Ella J Daly; Jaskaran B Singh; Maggie Fedgchin; Kimberly Cooper; Pilar Lim; Richard C Shelton; Michael E Thase; Andrew Winokur; Luc Van Nueten; Husseini Manji; Wayne C Drevets
Journal:  JAMA Psychiatry       Date:  2018-02-01       Impact factor: 21.596

4.  Gender differences in treatment response to sertraline versus imipramine in chronic depression.

Authors:  S G Kornstein; A F Schatzberg; M E Thase; K A Yonkers; J P McCullough; G I Keitner; A J Gelenberg; S M Davis; W M Harrison; M B Keller
Journal:  Am J Psychiatry       Date:  2000-09       Impact factor: 18.112

Review 5.  Gender differences in depression: implications for treatment.

Authors:  S G Kornstein
Journal:  J Clin Psychiatry       Date:  1997       Impact factor: 4.384

6.  Antidepressant efficacy of ketamine in treatment-resistant major depression: a two-site randomized controlled trial.

Authors:  James W Murrough; Dan V Iosifescu; Lee C Chang; Rayan K Al Jurdi; Charles E Green; Andrew M Perez; Syed Iqbal; Sarah Pillemer; Alexandra Foulkes; Asim Shah; Dennis S Charney; Sanjay J Mathew
Journal:  Am J Psychiatry       Date:  2013-10       Impact factor: 18.112

7.  Treatment-resistant depression: therapeutic trends, challenges, and future directions.

Authors:  Khalid Saad Al-Harbi
Journal:  Patient Prefer Adherence       Date:  2012-05-01       Impact factor: 2.711

8.  The role of ketamine in treatment-resistant depression: a systematic review.

Authors:  Gianluca Serafini; Robert H Howland; Fabiana Rovedi; Paolo Girardi; Mario Amore
Journal:  Curr Neuropharmacol       Date:  2014-09       Impact factor: 7.363

Review 9.  Comorbidity between post-traumatic stress disorder and major depressive disorder: alternative explanations and treatment considerations.

Authors:  Janine D Flory; Rachel Yehuda
Journal:  Dialogues Clin Neurosci       Date:  2015-06       Impact factor: 5.986

10.  Oral Ketamine in Treatment-Resistant Depression: A Clinical Effectiveness Case Series.

Authors:  Maryam I Al Shirawi; Sidney H Kennedy; Keith T Ho; Roisin Byrne; Jonathan Downar
Journal:  J Clin Psychopharmacol       Date:  2017-08       Impact factor: 3.153

View more
  15 in total

Review 1.  Hydroxynorketamines: Pharmacology and Potential Therapeutic Applications.

Authors:  Jaclyn N Highland; Panos Zanos; Lace M Riggs; Polymnia Georgiou; Sarah M Clark; Patrick J Morris; Ruin Moaddel; Craig J Thomas; Carlos A Zarate; Edna F R Pereira; Todd D Gould
Journal:  Pharmacol Rev       Date:  2021-04       Impact factor: 25.468

2.  Target deconvolution studies of (2R,6R)-hydroxynorketamine: an elusive search.

Authors:  Jordi Bonaventura; Juan L Gomez; Meghan L Carlton; Sherry Lam; Marta Sanchez-Soto; Patrick J Morris; Ruin Moaddel; Hye Jin Kang; Panos Zanos; Todd D Gould; Craig J Thomas; David R Sibley; Carlos A Zarate; Michael Michaelides
Journal:  Mol Psychiatry       Date:  2022-06-29       Impact factor: 15.992

Review 3.  Post-traumatic stress disorder: clinical and translational neuroscience from cells to circuits.

Authors:  Kerry J Ressler; Sabina Berretta; Vadim Y Bolshakov; Isabelle M Rosso; Edward G Meloni; Scott L Rauch; William A Carlezon
Journal:  Nat Rev Neurol       Date:  2022-03-29       Impact factor: 44.711

4.  Prophylactic (R,S)-Ketamine Is Effective Against Stress-Induced Behaviors in Adolescent but Not Aged Mice.

Authors:  Alessia Mastrodonato; Ina Pavlova; Noelle C Kee; Van Anh Pham; Josephine C McGowan; J John Mann; Christine A Denny
Journal:  Int J Neuropsychopharmacol       Date:  2022-06-21       Impact factor: 5.678

5.  Enhanced Fear Memories and Altered Brain Glucose Metabolism (18F-FDG-PET) following Subanesthetic Intravenous Ketamine Infusion in Female Sprague-Dawley Rats.

Authors:  Kennett D Radford; Rina Y Berman; Shalini Jaiswal; Sharon Y Kim; Michael Zhang; Haley F Spencer; Kwang H Choi
Journal:  Int J Mol Sci       Date:  2022-02-08       Impact factor: 5.923

6.  Acute Ketamine Facilitates Fear Memory Extinction in a Rat Model of PTSD Along With Restoring Glutamatergic Alterations and Dendritic Atrophy in the Prefrontal Cortex.

Authors:  Nathalie Sala; Caterina Paoli; Tiziana Bonifacino; Jessica Mingardi; Emanuele Schiavon; Luca La Via; Marco Milanese; Paolo Tornese; Ashok K Datusalia; Jessica Rosa; Roberta Facchinetti; Giulia Frumento; Giulia Carini; Floramarida Salerno Scarzella; Caterina Scuderi; Lia Forti; Alessandro Barbon; Giambattista Bonanno; Maurizio Popoli; Laura Musazzi
Journal:  Front Pharmacol       Date:  2022-03-17       Impact factor: 5.810

7.  BDNF-TrkB signaling-mediated upregulation of Narp is involved in the antidepressant-like effects of (2R,6R)-hydroxynorketamine in a chronic restraint stress mouse model.

Authors:  Lingsha Ju; Jiaojiao Yang; Tingting Zhu; Panmiao Liu; Jianjun Yang
Journal:  BMC Psychiatry       Date:  2022-03-15       Impact factor: 3.630

8.  Fluoroethylnormemantine, A Novel Derivative of Memantine, Facilitates Extinction Learning Without Sensorimotor Deficits.

Authors:  Briana K Chen; Gwenaëlle Le Pen; Adam Eckmier; Gilles Rubinstenn; Therese M Jay; Christine A Denny
Journal:  Int J Neuropsychopharmacol       Date:  2021-07-14       Impact factor: 5.176

9.  Sex Differences in the Sustained Effects of Ketamine on Resilience to Chronic Stress.

Authors:  Tracy Okine; Ryan Shepard; Elise Lemanski; Laurence Coutellier
Journal:  Front Behav Neurosci       Date:  2020-10-20       Impact factor: 3.558

Review 10.  Effects of Ketamine on Rodent Fear Memory.

Authors:  Kwang H Choi; Rina Y Berman; Michael Zhang; Haley F Spencer; Kennett D Radford
Journal:  Int J Mol Sci       Date:  2020-09-28       Impact factor: 5.923

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.